

CLAIMS AMENDMENTS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claim 1-6 (Canceled)

Claim 7 (Currently amended): An antisense oligonucleotide comprising a sequence ~~substantially~~100% complementary to SEQ ID NO: 5, wherein the oligonucleotide is ~~from about 8 up to~~ about 50 nucleotides in length.

Claim 8 (Canceled)

Claim 9 (Previously presented): The oligonucleotide of claim 7 labeled with a detectable label.

Claim 10 (Previously presented): The oligonucleotide of claim 9 wherein the label is selected from enzymes, ligands, chemicals which fluoresce and radioactive elements.

Claim 11 (Previously presented): The oligonucleotide of claim 7 wherein said oligonucleotide comprises at least one phosphorothioate linkage.

Claim 12 (Currently amended): A recombinant DNA molecule comprising a nucleic acid sequence which encodes on transcription an antisense RNA ~~from about 8 to~~ of up to about 50 nucleotides in length comprising a sequence that ~~which~~ is 100% complementary to SEQ ID NO:5.

Claim 13 (Original): The recombinant DNA molecule of claim 12, wherein said nucleic acid sequence is operatively linked to a transcription control sequence.

Claim 14 (Original): A cell line transfected with the recombinant DNA molecule of claim 13.

Claim 15 (Currently amended): An expression vector capable of expressing a nucleic acid which comprises a sequence that is 100% is substantially complementary to SEQ ID NO:5, wherein said nucleic acid inhibits the expression of KSR and is ~~from about 8~~ up to about 50 nucleotides in length.

Claim 16 (Canceled)

Claim 17 (Previously presented): A pharmaceutical composition comprising a therapeutically effective amount of the antisense oligonucleotide of claim 7 and a pharmaceutically acceptable carrier or diluent.

Claim 18 (Previously presented): A composition comprising the oligonucleotide of claim 7 and a pharmaceutically acceptable carrier or diluent.

Claim 19 (Previously presented): A composition comprising one or more chemotherapeutic or radiotherapeutic agent and the oligonucleotide of claim 7, wherein the oligonucleotide inhibits KSR expression.

Claim 20 (Currently amended): A composition comprising an expression vector and a pharmaceutically acceptable carrier or diluent, wherein said expression vector is capable of expressing a nucleic acid comprising a sequence that is 100% which is substantially complementary to SEQ ID NO:5, wherein said nucleic acid inhibits the expression of KSR and is ~~from about 8~~ up to about 50 nucleotides in length.

Claim 21-33 (Canceled)

Claim 34 (Currently amended): The oligonucleotide of claim 7, wherein the oligonucleotide is ~~from about 10 to about~~ up to 30 nucleotides in length.

Claim 35 (Currently amended): The oligonucleotide of claim 34, wherein the oligonucleotide is ~~from about 15 to about~~ up to 25 nucleotides in length.

Claim 36 (Canceled)

Claim 37 (Currently amended): The oligonucleotide of claim 7, which is complementary to ~~SEQ ID NO:5~~ and is 18 nucleotides in length.

Claim 38 (Previously presented): The oligonucleotide of claim 7, which comprises a modified backbone.

Claim 39 (Previously presented): A pharmaceutical composition comprising a therapeutically effective amount of the antisense oligonucleotide of claim 11 and a pharmaceutically acceptable carrier or diluent.

Claim 40 (Previously presented): A composition comprising the oligonucleotide of claim 11 and a pharmaceutically acceptable carrier or diluent.

Claim 41 (Previously presented): A composition comprising one or more chemotherapeutic or radiotherapeutic agent and the oligonucleotide of claim 11, wherein the oligonucleotide inhibits KSR expression.

Claim 42 (Previously presented): The oligonucleotide of claim 37, which is a phosphorothioate oligodeoxynucleotide.

Claim 43 (Previously presented): The oligonucleotide of claim 7, which is an oligodeoxynucleotide.

Claim 44 (Previously presented): The oligonucleotide of claim 38, wherein the modified backbone is selected from a phosphorothioate, phosphotriester, methyl phosphonate, polyamide, and a morpholino backbone.

Claim 45 (New): The recombinant DNA molecule of claim 12, wherein the antisense RNA is up to 30 nucleotides in length.

Claim 46 (New): The recombinant DNA molecule of claim 45, wherein the oligonucleotide is up to 25 nucleotides in length.

Claim 47 (New): The expression vector of claim 15, wherein the oligonucleotide is up to 30 nucleotides in length.

Claim 48 (New): The expression vector of claim 47, wherein the oligonucleotide is up to 25 nucleotides in length.

Claim 49 (New): The composition of claim 20, wherein the oligonucleotide is up to 30 nucleotides in length.

Claim 50 (New): The composition of claim 49, wherein the oligonucleotide is up to 25 nucleotides in length.